News
Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...
Roche discontinued the commercial and clinical use of Elevidys after two cases of fatal acute liver failure. The Swiss ...
The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...
Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...
Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...
Former club captain Barry Roche leaves Morecambe after 17 years at the Shrimps that spanned both playing and coaching roles.
Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...
Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...
Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...
Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...
Alainy Chiloh Roché is ready to tee up for a career in medicine or real estate development, but she will continue to improve ...
Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results